JP2023520506A - Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン - Google Patents

Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン Download PDF

Info

Publication number
JP2023520506A
JP2023520506A JP2022560168A JP2022560168A JP2023520506A JP 2023520506 A JP2023520506 A JP 2023520506A JP 2022560168 A JP2022560168 A JP 2022560168A JP 2022560168 A JP2022560168 A JP 2022560168A JP 2023520506 A JP2023520506 A JP 2023520506A
Authority
JP
Japan
Prior art keywords
rna
nanoparticles
cells
nucleic acid
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560168A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021202772A5 (https=
JP2023520506A5 (https=
Inventor
セイヤー、エリアス
メンデス－ゴメス、ヘクター、ルーベン
カーロ、ポール、アントニオ カスティロ
ジョーンズ、ノア、トーマス
ミッチェル、デュエイン、エー．
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2023520506A publication Critical patent/JP2023520506A/ja
Publication of JPWO2021202772A5 publication Critical patent/JPWO2021202772A5/ja
Publication of JP2023520506A5 publication Critical patent/JP2023520506A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022560168A 2020-04-01 2021-03-31 Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン Pending JP2023520506A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063003766P 2020-04-01 2020-04-01
US63/003,766 2020-04-01
US202063022999P 2020-05-11 2020-05-11
US63/022,999 2020-05-11
US202063128600P 2020-12-21 2020-12-21
US63/128,600 2020-12-21
PCT/US2021/025222 WO2021202772A1 (en) 2020-04-01 2021-03-31 Multilamellar rna nanoparticle vaccine against sars-cov-2

Publications (3)

Publication Number Publication Date
JP2023520506A true JP2023520506A (ja) 2023-05-17
JPWO2021202772A5 JPWO2021202772A5 (https=) 2024-03-22
JP2023520506A5 JP2023520506A5 (https=) 2024-03-22

Family

ID=75625672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560168A Pending JP2023520506A (ja) 2020-04-01 2021-03-31 Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン

Country Status (6)

Country Link
US (1) US20230226169A1 (https=)
EP (1) EP4126030A1 (https=)
JP (1) JP2023520506A (https=)
AU (1) AU2021247163A1 (https=)
CA (1) CA3174187A1 (https=)
WO (1) WO2021202772A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
EP4179328A2 (en) * 2020-07-10 2023-05-17 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
US20220042117A1 (en) * 2020-08-06 2022-02-10 Roche Molecular Systems, Inc. COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20240024466A1 (en) * 2020-12-07 2024-01-25 Trustees Of Tufts College Lipidoid compositions and methods of use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024010686A2 (en) * 2022-06-20 2024-01-11 The Trustees Of Columbia University In The City Of New York Vaccine tissue assays
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
CN107073028A (zh) * 2013-12-13 2017-08-18 南洋理工大学 多层纳米颗粒及其制作方法和使用方法
CN111630173A (zh) * 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
US10979132B2 (en) * 2018-08-10 2021-04-13 Qualcomm Incorporated Organization of inter-relay discovery reference signals
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AIMS BIOPHYSICS, vol. VOL:7,NR:4, JPN5023007995, 2020, pages 323 - 338, ISSN: 0005552605 *
ANTJE ZILLER: "Structural and functional characterisation of lipoplexes for tumour vaccination", マインツ・ヨハネス・グーテンベルク大学博士論文, JPN6025010144, 2019, ISSN: 0005552606 *
ASIAN PAC J ALLERGY IMMUNOL, vol. 38, no. 1, JPN6025010146, 2020, pages 1 - 9, ISSN: 0005552603 *
CLINICALTRIALS.GOV ARCHIVE [ONLINE], NCT04283461,[検索日2025.03.03],SAFETY AND IMMUNOGENICITY STUDY, JPN6025010145, 26 March 2020 (2020-03-26), ISSN: 0005552602 *
INT. J. MOL. SCI., vol. 19, no. 2890, JPN6025010143, 2018, pages 1 - 13, ISSN: 0005552604 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Also Published As

Publication number Publication date
US20230226169A1 (en) 2023-07-20
CA3174187A1 (en) 2021-10-07
AU2021247163A1 (en) 2022-10-20
WO2021202772A1 (en) 2021-10-07
EP4126030A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP2023520506A (ja) Ｓａｒｓ－ｃｏｖ－２に対する多層ｒｎａナノ粒子ワクチン
JP7096282B2 (ja) 免疫療法のためのｒｎａ製剤
CN115697298A (zh) 脂质纳米颗粒
US20160151482A1 (en) Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
CN116133640A (zh) 脂质纳米颗粒
US20250345417A1 (en) Compositions and methods for treatment of melanoma
US12514930B2 (en) Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
JP7783628B2 (ja) 多層ｒｎａナノ粒子
KR20210138586A (ko) 전립선암 치료용 rna
JP2023512707A (ja) Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用
US20230346700A1 (en) Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
KR20220010500A (ko) 난소암 치료용 rna
US20240238418A1 (en) Car t cell therapy method
KR20210052924A (ko) 작은 지질 나노 입자 및 이를 포함하는 암 백신
US20240299516A1 (en) Multilamellar rna nanoparticle vaccine against cancer
CA3166934A1 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
HK40110647A (zh) 用於治疗黑素瘤的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221109

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224